Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib in FGFR1-rearranged Myeloid/Lymphoid Tumors
NCT05521204Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1), sponsored by First Affiliated Hospital of Soochow University. Started Sep 2022; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
Myeloid/lymphoid neoplasm with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1)
Beyond the preview
Go deeper on NCT05521204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521204.